<ul>
<li>Cutia Therapeutics held its annual general meeting on June 26, 2026.    *      Shareholders adopted the audited consolidated financial statements and related directors’ and auditors’ reports for the year ended Dec. 31, 2025. *      Director appointments were endorsed, including reappointments of non-executive and independent non-executive directors.     *      Ernst &amp; Young was reappointed as auditor.     *      Shareholders granted mandates to repurchase shares, issue additional shares, and extend the issuance mandate by the number of shares repurchased. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260626-12216900), on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

02487

<p>Cutia Therapeutics passed resolutions at its June 26, 2026 AGM. Shareholders approved the 2025 audited financial statements, reappointed Ernst & Young as auditor, and endorsed director appointments. Additionally, mandates were granted for share repurchases, new share issuances, and extending the issuance mandate by the number of repurchased shares.</p>

Cutia Therapeutics AGM resolutions passed in shareholder vote